A5025182598- Schizophrenia research and treatment
- Diet and metabolism studies
- Diabetes Treatment and Management
- Tryptophan and brain disorders
- Metabolism, Diabetes, and Cancer
- Bipolar Disorder and Treatment
- Pharmacology and Obesity Treatment
- Regulation of Appetite and Obesity
- Diabetes Management and Research
- Adipose Tissue and Metabolism
- Pancreatic function and diabetes
- Behavioral Health and Interventions
- Neurotransmitter Receptor Influence on Behavior
- Gut microbiota and health
- Parkinson's Disease Mechanisms and Treatments
- Mental Health and Psychiatry
- Health Policy Implementation Science
- Smoking Behavior and Cessation
- Neurological disorders and treatments
- Diabetes and associated disorders
- Receptor Mechanisms and Signaling
- Obsessive-Compulsive Spectrum Disorders
- Gastrointestinal motility and disorders
- Pharmaceutical studies and practices
- Attention Deficit Hyperactivity Disorder
Centre for Addiction and Mental Health
2016-2025
University of Toronto
2016-2025
Diabetes Canada
2018-2025
University of Copenhagen
2023-2024
Glostrup Hospital
2023-2024
Copenhagen University Hospital
2024
Canada Research Chairs
2011-2023
McMaster University
2022-2023
Impact
2023
Dalhousie University
2008-2020
KEY POINTS Obesity is a complex chronic disease in which abnormal or excess body fat (adiposity) impairs health, increases the risk of long-term medical complications and reduces lifespan.[1][1] Epidemiologic studies define obesity using mass index (BMI; weight/height2), can stratify
Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists (GLP1-RA) have shown promise in management of obesity general population, with preliminary evidence supporting efficacy AAWG. Semaglutide a weekly injectable GLP-1RA which received recent approval and noted superiority over other GLP-1RAs. This study explored tolerability semaglutide AAWG among...
Atypical antipsychotics may "directly" influence glucose homeostasis, increasing risk of type 2 diabetes independently changes in adiposity. Animal models suggest direct effects after even a single dose certain atypical on dysregulation. Here, we investigated single-dose olanzapine (OLA) metabolism healthy volunteers, thereby minimizing confounding the illness schizophrenia and In randomized double-blind crossover design, 15 subjects were administered 10 mg OLA or placebo at 7:00 A.M....
Food addiction is a debated topic in neuroscience. Evidence suggests diabetes related to reduced basal dopamine levels the nucleus accumbens, similar persons with drug addiction. It unknown whether insulin sensitivity endogenous ventral striatum of humans. We examined this using agonist D2/3 receptor radiotracer [11C]-(+)-PHNO and an acute depletion challenge. In separate sample healthy persons, we could alter sensitivity. Insulin was estimated for each subject from fasting plasma glucose...
Abstract Antipsychotic (AP)-naive first-episode psychosis (FEP) patients display early dysglycemia, including insulin resistance and prediabetes. Metabolic dysregulation may therefore be intrinsic to spectrum disorders (PSDs), independent of the metabolic effects APs. However, potential biological pathways that overlap between PSDs dysglycemic states remain identified. Using meta-analytic approaches transcriptomic datasets, we investigated whether AP-naive FEP share overlapping gene...
Early and effective treatment in first-episode schizophrenia is associated with better outcomes. Evidence suggests that response generally robust a first antipsychotic trial, but marked reduction rate observed among patients for whom second trial warranted, even further reductions are seen subsequent trials. Clozapine, the of choice refractory schizophrenia, routinely employed only as third-line treatment, it has been shown to markedly enhance response, when compared other atypical...